Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma

What is the purpose of this trial?

Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving radiation with concomitant and adjuvant temozolomide versus radiation with adjuvant PCV is more effective in treating anaplastic glioma or low grade glioma.


Participation Guidelines

Ages: 18 years and younger

Gender: Both


Alliance Cooperative Group

Start Date: 12/27/2016

End Date: 12/01/2018

Last Updated: 02/22/2018

Study HIC#: 1603017494

Get Involved

For more information about this study, contact:
Tenzin Choezom
+1 203-785-3865
t.choezom@yale.edu

Investigators

Kevin Patrick Becker

Principal Investigator

Sub-Investigators